SCHEMBL7109255

SCHEMBL7109255

O=C1NCC(c2ccc(Cl)cc2)C2(CCN(C(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC2)O1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RHOC P08134 5/20 0.49
RHOA P61586 5/20 0.49
CYP2C9 P11712 6/20 0.46
TSHR P16473 6/20 0.46
USP2 O75604 8/20 0.45
CYP3A4 P08684 7/20 0.45
HSD17B10 Q99714 3/20 0.45
HIF1A Q16665 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 2/20 0.45
CYP2D6 P10635 4/20 0.45
CYP2C19 P33261 2/20 0.45
CYP1A2 P05177 2/20 0.45
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7109251 1.00 RHOC (0.49) RHOCRHOACYP2C9TSHRUSP2
SCHEMBL5012620 0.91 USP2 (0.43) RHOCRHOACYP2C9TSHRUSP2
SCHEMBL5012659 0.91 USP2 (0.43) RHOCRHOACYP2C9TSHRUSP2
SCHEMBL5012152 0.90 CYP3A4 (0.53) CYP2C9TSHRUSP2CYP3A4HSD17B10
SCHEMBL5010920 0.90 CYP3A4 (0.53) CYP2C9TSHRUSP2CYP3A4HSD17B10
SCHEMBL5014232 0.90 CYP3A4 (0.46) RHOCRHOACYP2C9TSHRUSP2
SCHEMBL5012629 0.90 CYP3A4 (0.46) RHOCRHOACYP2C9TSHRUSP2
SCHEMBL5010895 0.90 TSHR (0.46) RHOCRHOACYP2C9TSHRUSP2
SCHEMBL5012597 0.90 TSHR (0.46) RHOCRHOACYP2C9TSHRUSP2
SCHEMBL7219708 0.87 HIF1A (0.46) CYP2C9TSHRUSP2CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390372-A1 1-OXA-3,9-DIAZA-SPIRO'5,5!UNDECAN-2-ONES DERIVATIVES AND ITS USE AS ANTAGONIST OF THE NEURIKININ RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2004-02-25 EP disclosed
US-6599900-B2 Antiinflammatory agents; headaches; antiarthritic agents SYNTEX (U.S.A.) LLC 2003-07-29 US disclosed
US-20030004163-A1 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones SYNTEX (U.S.A) LLC 2003-01-02 US disclosed
WO-2002092604-A1 1-OXA-3,9-DIAZA-SPIRO'5,5!UNDECAN-2-ONES DERIVATIVES AND ITS USE AS ANTAGONIST OF THE NEURIKININ RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004163-A1 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones OXER1, NR4A1, OXGR1 RHOC 4590/4885RHOA 4751/4885CYP2C9 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.